Bank of New York Mellon Corp Has $7.24 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Bank of New York Mellon Corp cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 252,687 shares of the specialty pharmaceutical company’s stock after selling 11,763 shares during the quarter. Bank of New York Mellon Corp owned about 0.78% of Collegium Pharmaceutical worth $7,239,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical in the third quarter valued at $757,000. Barclays PLC raised its stake in shares of Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $695,000 after purchasing an additional 1,731 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Collegium Pharmaceutical by 1,532.2% in the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after purchasing an additional 35,439 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on COLL. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $43.60.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. The trade was a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,961 shares of company stock worth $3,146,634 over the last three months. 3.98% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $29.46 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a fifty day moving average price of $30.85 and a two-hundred day moving average price of $32.96. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29. The firm has a market capitalization of $927.58 million, a P/E ratio of 12.70 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. As a group, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.